Top Markets
Coin of the day
XORTX Therapeutics Inc. XORTX Therapeutics Inc.

XORTX Therapeutics Inc.

XRTX
Rank in Stocks #39289
Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm... Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic syndrome, and infections. The company's pipeline includes XRx-008, a late-stage clinical program addressing autosomal dominant polycystic kidney disease; XRx-101, an agent designed to reduce uric acid levels in COVID-19 patients to prevent acute kidney injury and its associated health issues; and XRx-221, a series of xanthine oxidase inhibitor candidates aimed at treating diabetic nephropathy. Furthermore, XORTX Therapeutics collaborates with the Icahn School of Medicine to research the occurrence of acute kidney injury and elevated uric acid in patients hospitalized with COVID-19.
Share Price
$2.04
Last synced: 2026-08-13
Market Cap
$568.21K
Change (1 day)
-0.71%
Change (1 year)
-90.45%
Country
CA
Trade XORTX Therapeutics Inc. (XRTX)

Category

P/S ratio for XORTX Therapeutics Inc. (XRTX)
P/S ratio as of 2026 TTM: 0
According to XORTX Therapeutics Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for XORTX Therapeutics Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE